Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells in Mice.
Aiello, Robert J.; Bourassa, Patricia-Ann; Lindsey, Saralyn; Weng, Weifan; Freeman, Ann; Showell, Henry J.
[Miscellaneous Article] Arteriosclerosis, Thrombosis & Vascular Biology. 22(3):443-449, March 2002.

(Format: HTML, PDF)

mdash;: Leukotriene B4 (LTB4) is a potent chemotactic agent that activates monocytes through the LTB4 receptor (BLTR). We tested the hypothesis that LTB4 receptor blockade would slow atherosclerotic progression by inhibiting monocyte recruitment. Homozygous low-density receptor knockout (LDLr-/-) mice and apolipoprotein E deficient (apoE-/-) mice were treated with a specific LTB4 receptor antagonist, CP-105,696, for 35 days. In apoE-/-mice, treatment with the LTB4 antagonist did not affect plasma lipid concentrations but significantly reduced CD11b levels both in vascular lesions and whole blood. Compared with age-matched controls, lipid accumulation and monocyte infiltration were significantly reduced in treated apoE-/- mice at all time points tested. Lesion area reduction was also demonstrated in LDLr-/- mice maintained on a high-fat diet. LTB4 antagonism had no significant effect on lesion size in mice possessing the null alleles for another chemotactic agent, monocyte chemoattractant protein-1 (MCP-1-/-xapoE-/-), suggesting MCP-1 and LTB4 may either interact or exert their effects by a common mechanism. These results demonstrate that in a preclinical model of atherosclerosis LTB4 receptor blockade reduces lesion progression and further suggest a previously unrecognized role for LTB4 or other oxidized lipids recognized by the BLTR receptor in the pathogenesis of this disease.

(C) 2002 American Heart Association, Inc.